Decades ago, a chaperone was a person who accompanied an unmarried girl in public. Now, however, we’re learning that a chaperone — in this…
A new study by Houston Methodist scientists finds that a protein linked to ovarian cancer may contribute to the development of Alzheimer’s disease. The…
Biogen has agreed to buy an experimental Alzheimer’s and Parkinson’s treatment from Pfizer, the company announced Monday. In the agreed deal, Biogen will pay…
Can a simple eye exam detect Alzheimer’s disease? Researchers in Rhode Island and Florida have launched a $5 million study that could allow doctors…
Scientists are continuing to search for answers to Alzheimer’s disease and other dementias, targeting beta-amyloid and tau protein, inflammation, and genetic factors in research…
Scientists are increasingly certain that Alzheimer’s and other dementias are caused by many factors. Genetics certainly play a major role, but researchers are increasingly…
When it comes to Alzheimer’s, what happens first: beta amyloid plaques, or the visible personality and cognitive changes common with the disease? Researchers have…
With repeated drug failures to treat Alzheimer’s disease in recent years, scientists are racing to find a vaccine to prevent the disease from evolving….
Chinese officials announced conditional approval to a seaweed-based drug in November. Now, it’s available on the Chinese market. Oligomannate is the first drug to…
The exact causes behind dementia are varied and at times unclear. We know that genetic factors — like carrying the APOE4 gene — can…
Having conversations about end of life care is difficult at any age, but for seniors, it can be especially difficult. Facing your mortality is…
Talk with an Alzheimer’s researcher and you’ll likely hear the same lament: Finding a treatment or cure is incredibly challenging because scientists are not…
As research into a cure — or at least treatment — for Alzheimer’s continues, scientists are looking beyond the pathways of targeting tau or…
Biogen announced this week that it was cancelling the dementia drug it was testing in a Phase 2 trial that aimed to fight tau…
Congressional leaders gave the Alzheimer’s and dementia communities an early holiday present this week, announcing an additional $350 million annual appropriation for research into…